New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges
Abstract
This book illustrates some of the most recent research efforts that have been made in lowering plasma cholesterol levels in patients with CVD. Selected articles aimed to illuminate advances and urgent challenges in the management of CVD, including disease management using statin-combined therapeutic strategies.
Keywords
apolipoprotein; lipids; risk stratification; proprotein convertase subtilisin-kexin type 9 (PCSK9); vaspin; sphingolipids; PCSK9; ceramides; atrial fibrillation; circular RNA; STEMI; cholesterol; lipoproteins; cardiovascular disease (CVD); coronary artery bypass grafting; atherosclerosis; statin; LDL subfractions; acute kidney injury; dyslipidemia; gene expression; NSTEMI; NAFLD; hyperlipidemia; nonstatin; cholesteryl ester transfer protein; low-density lipoprotein cholesterol; anacetrapib; HDL; acute coronary syndrome; miRNA; cardiovascular risk; pleiotropic actions; genetic; ABCA1; sdLDL; cardiovascular disease; proprotein convertase subtilisin/kexin type 9; inclisiran; reverse cholesterol transport; sterol; small interfering RNA (siRNA); RNA-binding proteins; cardiovascular diseases; NASH; low-density lipoprotein-cholesterol (LDL-C); stroke; nutrigenetics; type 2 diabetes; statins; sphingomyelin; hepatic fibrosis; diabetesISBN
9783039216772, 9783039216765Publisher website
www.mdpi.com/booksPublication date and place
2019Classification
Biology, life sciences